Literature DB >> 16480833

The biology of Ku and its potential oncogenic role in cancer.

Charles Gullo1, Melvin Au, Ge Feng, Gerrard Teoh.   

Abstract

Ku is a heterodimeric protein made up of two subunits, Ku70 and Ku80. It was originally identified as an autoantigen recognized by the sera of patients with autoimmune diseases. It is a highly versatile regulatory protein that has been implicated in multiple nuclear processes, e.g., DNA repair, telomere maintenance and apoptosis. Accordingly, Ku is thought to play a crucial role in maintenance of chromosomal integrity and cell survival. Recent reports suggest that there is a positive relationship between Ku and the development of cancer, making Ku an important candidate target for anticancer drug development. Specifically, prior studies suggest that a delicate balance exists in Ku expression, as overexpression of Ku proteins promotes oncogenic phenotypes, including hyperproliferation and resistance to apoptosis; whereas deficient or low expression of Ku leads to genomic instability and tumorigenesis. Such observations through various experimental models indicate that Ku may act as either a tumor suppressor or an oncoprotein. Hence, understanding the link between the various functions of Ku and the development of cancer in different cell systems may help in the development of novel anticancer therapeutic agents that target Ku. These studies may also increase our understanding of how Ku autoantibodies are generated in autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16480833     DOI: 10.1016/j.bbcan.2006.01.001

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  48 in total

1.  Early evaluation of the apoptotic index ratio is useful in predicting the efficacy of chemoradiotherapy in esophageal squamous cell carcinoma.

Authors:  Jun Sobajima; Kensuke Kumamoto; Norihiro Haga; Junichi Tamaru; Takeo Takahashi; Tatsuya Miyazaki; Hideyuki Ishida
Journal:  Oncol Lett       Date:  2011-11-02       Impact factor: 2.967

2.  Poly(ADP-ribose) polymerase 1 interaction with apurinic/apyrimidinic sites.

Authors:  S N Khodyreva; E S Ilina; M M Kutuzov; M V Sukhanova; O I Lavrik
Journal:  Dokl Biochem Biophys       Date:  2010 Mar-Apr       Impact factor: 0.788

3.  Ku70 is stabilized by increased cellular SUMO.

Authors:  Vyacheslav Yurchenko; Zhu Xue; Vivian Gama; Shigemi Matsuyama; Moshe J Sadofsky
Journal:  Biochem Biophys Res Commun       Date:  2007-12-04       Impact factor: 3.575

4.  Tagging of endogenous genes in a Toxoplasma gondii strain lacking Ku80.

Authors:  My-Hang Huynh; Vern B Carruthers
Journal:  Eukaryot Cell       Date:  2009-02-13

5.  Identification of Ku80 subunit of Ku antigen as a protein reactive to apurinic/apyrimidinic sites.

Authors:  E S Ilina; O I Lavrik; S N Khodyreva
Journal:  Dokl Biochem Biophys       Date:  2009 Jan-Feb       Impact factor: 0.788

6.  Mutations to Ku reveal differences in human somatic cell lines.

Authors:  Kazi R Fattah; Brian L Ruis; Eric A Hendrickson
Journal:  DNA Repair (Amst)       Date:  2008-04-01

7.  Apigenin induces apoptosis by targeting inhibitor of apoptosis proteins and Ku70-Bax interaction in prostate cancer.

Authors:  Sanjeev Shukla; Pingfu Fu; Sanjay Gupta
Journal:  Apoptosis       Date:  2014-05       Impact factor: 4.677

8.  Role of Ku70 and Bax in epigallocatechin-3-gallate-induced apoptosis of A549 cells in vivo.

Authors:  Jing-Jing Li; Qi-Hua Gu; Min Li; Hua-Ping Yang; Li-Ming Cao; Cheng-Ping Hu
Journal:  Oncol Lett       Date:  2012-10-16       Impact factor: 2.967

9.  Prognostic significance of ataxia-telangiectasia mutated, DNA-dependent protein kinase catalytic subunit, and Ku heterodimeric regulatory complex 86-kD subunit expression in patients with nonsmall cell lung cancer.

Authors:  Jinliang Xing; Xifeng Wu; Ara A Vaporciyan; Margaret R Spitz; Jian Gu
Journal:  Cancer       Date:  2008-06-15       Impact factor: 6.860

10.  A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure.

Authors:  Petra Willems; Kim De Ruyck; Rudy Van den Broecke; Amin Makar; Gianpaolo Perletti; Hubert Thierens; Anne Vral
Journal:  J Cancer Res Clin Oncol       Date:  2009-02-15       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.